dichlororibofuranosylbenzimidazole has been researched along with Cancer of Larynx in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Gong, S | 1 |
| Fu, Y | 1 |
| Xue, Q | 1 |
| Chen, G | 1 |
| Liu, Y | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Cancer of Larynx
| Article | Year |
|---|---|
Effect of DRB on the biological characteristics of human laryngeal carcinoma Hep-2 cell line.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Collagen; Dichlor | 2007 |